Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.

Keeping Up With Market Trends

4 stars

166111 Reads | 165 Comments | 22 People call this a favourite

Looking at active issues and news to make the right move when investing.

  • Theralase destroys 98% of cancer cells in animal model

    244 Reads | 0 Comments | 9 days ago

    Theralase destroys 98% of cancer cells in animal model 2015-07-22 07:27 ET - News Release   Mr. Roger Dumoulin-White reports THERALASE ACHIEVES 98% DESTRUCTION OF BLADDER CANCER Theralase Technologies Inc. has achieved near-complete destruction (approximately 98 per cent) of bladder cancer in an animal model. The company previously announced on Dec. 9 and 23, 2014...

  • Antibe Therapeutics Announces Addition to Product Pipeline

    53 Reads | 0 Comments | 9 days ago

    Antibe Therapeutics Announces Addition of Aspirin Derivative to Its Product Pipeline and Provides an Update on Validation Studies July 20, 2015 01:30 PM Eastern Daylight Time TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE) is pleased to announce the addition to its product pipeline of ATB-340, a hydrogen...

  • Antibe Therapeutics adds ATB-340 to product pipeline

    187 Reads | 0 Comments | 10 days ago

      Antibe Therapeutics adds ATB-340 to product pipeline 2015-07-20 13:34 ET - News Release   Mr. Dan Legault reports ANTIBE THERAPEUTICS ANNOUNCES ADDITION OF ASPIRIN DERIVATIVE TO ITS PRODUCT PIPELINE AND PROVIDES AN UPDATE ON VALIDATION STUDIES Antibe Therapeutics Inc. has added ATB-340, a hydrogen-sulphide-releasing derivative of aspirin, to its product pipeline...

  • ATB-346 shows promise because it spares the small intestine of injury

    60 Reads | 0 Comments | 13 days ago

    Promising new NSAID-derivative may be well-tolerated by chronic pain sufferers Date: July 1, 2015 Millions of people in the U.S. use nonsteroidal anti-inflammatory drugs (NSAIDs) to treat pain and inflammation. For osteoarthritis, rheumatoid arthritis and other chronic pain conditions, NSAIDs such as naproxen (ALEVE) are...

  • Magazine got it wrong in so many ways

    93 Reads | 0 Comments | July 16, 2015

    2015-07-15 22:15 ET - In the News   The Successful Investor, in its July, 2015, issue, refreshes its buy of Bombardier Inc., recently $2.53. The Investor said buy 20 times from August, 2000, to February, 2015, at prices ranging from $3.28 to $23. Assuming an investment of $1,000 for each of the 20 buys, the $20,000 position would now be worth $8,774. The train and aircraft maker...

  • Antibe Therapeutics grants stock options

    117 Reads | 0 Comments | July 15, 2015

    Antibe Therapeutics Announces Change in CFO Position and Granting of Employee Stock Options 13 Jul 2015 - ACQUIREMEDIA TORONTO--(BUSINESS WIRE)--Jul. 13, 2015-- Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE) today announced that Dr. Michael Bumby has resigned as CFO, effective August 1, 2015. Antibe wishes to thank Dr. Bumby for his efforts in taking...

  • UrtheCast closes Earth observation business acquisition

    31 Reads | 0 Comments | July 15, 2015

      UrtheCast closes Earth observation business acquisition 2015-07-15 08:44 ET - News Release   Mr. Scott Larson reports URTHECAST CLOSES ACQUISITION OF EARTH OBSERVATION SATELLITES AND BUSINESS OPERATIONS FROM ELECNOR UrtheCast Corp.'s subsidiary has closed its previously announced acquisition of the Earth observation business doing business as Deimos Imaging and...

  • Sleep Country Canada Holdings to list on TSX July 16

    124 Reads | 0 Comments | July 14, 2015

      Sleep Country Canada Holdings to list on TSX July 16 2015-07-14 17:53 ET - New Listing   Sleep Country Canada Holdings Inc. will begin trading on the Toronto Stock Exchange as an industrial issuer at the open on Thursday, July 16, 2015, according to the TSX. The exchange reports the company is Canada's leading mattress retailer, operating under the the retail banners...